REPLIGEN CORP Payments to Acquire Held-to-maturity Securities
REPLIGEN CORP (RGEN) reported Payments to Acquire Held-to-maturity Securities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2025-03-14
- REPLIGEN CORP payments to acquire held-to-maturity securities for fiscal 2024 was $0.00.
- REPLIGEN CORP payments to acquire held-to-maturity securities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- REPLIGEN CORP payments to acquire held-to-maturity securities for fiscal 2022 was $100.00M.
- REPLIGEN CORP payments to acquire held-to-maturity securities for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-14 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-14 |
| 2022-12-31 | $100.00M 10-K · filed 2025-03-14 |
| 2021-12-31 | $0.00 10-K/A · filed 2024-11-18 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |